Search

Iomethin I-125

Iomethin I-125 is a small molecule drug. Iomethin I-125 has a monoisotopic molecular weight of 353.05 Da.

Oliceridine

[A218026, A218031] By acting as a biased agonist, oliceridine provides comparable analgesia compared with traditional opioids such as [morphine] at a comparable or decreased risk of opioid-related adverse … [A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor

PXT 3003

PXT 3003 is in phase 3 clinical trials for the treatment of Charcot-Marie-Tooth disease type 1A in adults.

Darapladib

DA-6886

DA-6886 has been used in trials studying the treatment of Irritable Bowel Syndrome.

EA-2353

EA-2353 is a small molecule inhibitor of kinase mediators of the Wnt pathway.

Tisotumab vedotin

Tisotumab vedotin is a tissue factor-directed antibody-drug conjugate (ADC) comprised of an anti-tissue factor (TF) human IgG1-kappa antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting … agent, via a protease-cleavable valine-citrulline linker.

Aleglitazar

Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. … In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects

Prednicarbate

It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy. … Prednicarbate is a relatively new topical corticosteroid drug that displays a similar potency as [hydrocortisone].

Bermekimab

Bermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).